NOTICE: Many events listed here have been canceled or postponed due to the Covid-19 emergency. It is best to call ahead or check with organizer's websites to verify the status of any local event.

Change Location × London, UK

    Recent Locations

      OBN BioTuesday: 'What's New in Protein Expression - Taking New Therapeutic Drugs to the Clinic' in London

      • OBN BioTuesday: 'What's New in Protein Expression - Taking New Therapeutic Drugs to the Clinic' Photo #1
      1 of 1
      October 22, 2019

      Tuesday   5:30 PM

      Kings College London , Strand
      London, Greater London

      • No Performers Listed
      OBN BioTuesday: 'What's New in Protein Expression - Taking New Therapeutic Drugs to the Clinic'

      OBN BioTuesday: 'What's New in Protein Expression - Taking New Therapeutic Drugs to the Clinic',  kindly sponsored by Lonza Over the past few years the number of recombinant proteins used for therapeutic applications has increased exponentially. The technology involves complex glycoproteins and antibodies with relatively high production needs. These requirements have driven the development of a variety of improvements in protein expression technology, particularly involving mammalian and microbial culture systems. Therapeutic protein drugs are an important class of drugs particularly in areas of unmet need. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, infectious disease, autoimmunity/inflammation, and genetic disorders. The latest advances in protein-engineering technologies have allowed drug developers and manufacturers to refine and exploit desirable functional characteristics of proteins of interest while maintaining or enhancing product safety or efficacy or both. Manufacturing recombinant therapeutic proteins at an industrial-scale is more than having large steel tanks, large plastic bags, or even high productivities. To be successful you need : 1. To produce a therapeutic drug with the required cGMP quality attributes: potency or strength, identity, safety profile, quality, and purity – collectively, these attributes are described by the acronym SISQP. 2. Production of the required mass of product to service the patient populations and simultaneously satisfy the needs of SISQP testing. 3. Time from discovery to clinic or to market needs to be considered. 4. Cost-of-goods becomes important for a new therapeutic drug as payers increasingly require both competitive pricing & proven value. Initially, speed trumps this fourth point (cost-of-goods), but the risks of fast but less information need to be balanced with the impact of more certainty and longer timelines Choice of the right expression and production platform upfront reduces the likelihood and impact of risks associated with these four points, alongside early identification of negative characteristics of the protein molecule, and increases the probability of a successful transition from Phase 1 to approval. Programme & Speakers 17:45    Registration & Networking 18:30    Welcome by John Harris, CEO, OBN & Sarah Holland,  Global Head of Licensing and Head of Bio Division R&D at Lonza 18:35    Keynote: Andy Racher, Director, R&D IP Strategy at Lonza will present on: "Recombinant Proteins from Mammalian Cells. Where are we? Where might we go?" 18:55    Keynote: Hari Kumar, who is an experienced Pharmaceutical Executive, Independent Board Member, whose past roles include CEO of Adheron Therapeutics, will provide an industry perspective on: 'What to consider when moving therapeutic proteins from development to first in human trials' 19.20   Keynote: Noel Smith | Principal Group Leader, Lonza - "Early developability assessment tools – successful de-risking strategies to support progression of biologics from discovery to development" 19.40   Company Insight: Tom Mander, COO, Domainex, will address: ‘Combinatorial Domain Hunting - A proven, high throughput approach to overcome challenges in protein expression to enable structure-based drug design’ 19.55 Company Insight: Richard Hart, Director of Business Development, Leaf Expression Systems 20:10 Company Insight: Geoff Hale, Director of Absolute Antibody  20.20   Audience Q&A with all speakers 20:35    Drinks & Networking 21:30   Event Close TICKETS OBN Members:  One Complimentary OBN Member Additional Ticket:  £25.00 plus VAT PHD Students & Research Scientists: Complimentary Non Members, Non R&D Companies: £50.00 plus VAT Kindly Supported by:

      Categories: Health & Wellness | Outdoors & Recreation

      Event details may change at any time, always check with the event organizer when planning to attend this event or purchase tickets.

      Hotels and Airbnbs near OBN BioTuesday: 'What's New in Protein Expression - Taking New Therapeutic Drugs to the Clinic'. Book your stay now!